SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Bolin Niu, Kimberly A Forde, David S. Goldberg, Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data, Pharmacoepidemiology and Drug Safety, 2015, 24, 1
  2. 2
    Z. M. Younossi, H. Park, S. Saab, A. Ahmed, D. Dieterich, S. C. Gordon, Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection, Alimentary Pharmacology & Therapeutics, 2015, 41, 6
  3. 3
    Zobair M. Younossi, Yushan Jiang, Nathaniel J. Smith, Maria Stepanova, Rachel Beckerman, Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States, Hepatology, 2015, 61, 5
  4. 4
    S. Saab, S. C. Gordon, H. Park, M. Sulkowski, A. Ahmed, Z. Younossi, Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection, Alimentary Pharmacology & Therapeutics, 2014, 40, 6
  5. 5
    Jayant A. Talwalkar, Health services and policy research in hepatology, Current Opinion in Gastroenterology, 2014, 30, 3, 272

    CrossRef

  6. 6
    Christoph Höner zu Siederdissen, Markus Cornberg, Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection, Clinical Investigation, 2014, 4, 4, 361

    CrossRef